ALB and neoplasm: Vaccinia VG9/(SST-14)2-HSA possesses even weaker oncolytic ability than VG9/TK− due to the insertion of exogenous gene, however, the expressed (SST-14)2-HSA can improve the oncolytic ability of sstrs-positive tumor cells through the interaction with sstrs.